Featured NCORP Trials

MUSC Hollings Cancer Center and its affiliate network are one of just 14 National Cancer Institute Minority/Underserved Community Oncology Research Program (NCORP-MU) sites in the country. The goal of the NCORP-MU program is to make cancer clinical trials more accessible by offering them in the communities where patients live, with a particular focus on areas with minority and underserved populations. The NCORP-MU program is part of Hollings' larger efforts to reduce health disparities and unequal access to care across South Carolina.

There are a number of important NCORP trials studying ways to improve cancer care delivery, prevention, and symptom management. Details on a few of these featured NCORP trials are listed below.

If you or someone you know would like more information about how to participate, click on the study-specific links to submit your information. It will be reviewed by a member of our Hollings clinical trials team. For more information, you may also submit a contact form and someone will reach out to you.

Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS)

Principal Investigator: Dr. Sarah Tucker Price

IMPACTS has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services.

IMPACTS is an internet-based study used to determine if the program will reduce pain or improve pain impact on daily activities. This study compares the usual pain care plus pain education versus the internet-based pain program plus usual care with pain education. To complete an initial eligibility screening, follow the link below.

IMPACTS Eligibility Screening Survey

Early Onset Malignancies Initiative (EOMI)

Principal Investigator: Dr. Steven Carroll

The EOMI study is investigating the changes that can cause cancers to occur at an earlier age than might be expected (early cancer onset). This is a specimen and data collection study where specimens (blood and excess tissues not needed for diagnosis) and clinical data will be collected for genetic testing.

Another important focus of this study is to address disparities in cancer, that is, why some racial and ethnic groups bear a heavier burden compared to the general population (more cases, poorer outcomes, higher death rates). This information should lead to better ways to prevent, detect, and treat cancer, as well as help to improve outcomes in racial and ethnic groups. To complete an initial eligibility screening, follow the link below.

EOMI Eligibility Screening Survey

Immune Checkpoint Inhibitor Toxicity (I CHECK-IT)

Principal Investigator: Dr. Frank Brescia

The objective of the I CHECK-IT study is to develop and independently validate a risk prediction model for Adverse Events Grade 3 or higher non-hematological immune-related adverse events in the first year of immune checkpoint inhibitor (ICI)-based therapy for the treatment of solid tumors.

Patients on this study will be observed while receiving immune therapy treatment for Adverse Events of Grade 3 or higher for toxicity. To complete an initial eligibility screening, follow the link below.

I CHECK-IT Eligibility Screening Survey